Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™
April 01, 2021 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax...
Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate
March 22, 2021 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced today that it has retained Summit Biosciences, a world-wide...
AdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection
March 15, 2021 07:00 ET
|
Altimmune, Inc.
New Findings from Ongoing Collaborations with University of Alabama at Birmingham and Saint Louis University Studies Show Complete Protection Against Lethal Challenge and Dramatic Reduction in...
Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza
March 12, 2021 01:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its...
Altimmune to Present at Upcoming Conferences
March 08, 2021 16:01 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present...
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
February 25, 2021 07:03 ET
|
Altimmune, Inc.
Nasal spray may offer room temperature distribution that could reduce logistical challenges for healthcare systems and providers Intranasal administration targets the virus at its point of entry and...
Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update
February 25, 2021 07:00 ET
|
Altimmune, Inc.
Enrollment in the Phase 1 AdCOVID™ Clinical Trial has Commenced Development of AdCOVID Vectors Targeting Emerging Variants of the SARS-CoV-2 Virus has Begun ALT-801 is Progressing Through...
Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
February 22, 2021 16:30 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial...
Altimmune Announces FDA Clearance of AdCOVID™ IND Application
February 17, 2021 07:02 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
December 30, 2020 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its...